Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

NFκB and Kidney Injury.

Song N, Thaiss F, Guo L.

Front Immunol. 2019 Apr 16;10:815. doi: 10.3389/fimmu.2019.00815. eCollection 2019. Review.

2.

An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.

Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B; Athena Study Group.

Kidney Int. 2019 Jul;96(1):231-244. doi: 10.1016/j.kint.2019.01.041. Epub 2019 Feb 27.

PMID:
31027892
3.

Donor derived HLA-G polymorphisms have a significant impact on acute rejection in kidney transplantation.

Janssen M, Thaiss F, Nashan B, Koch M, Thude H.

Hum Immunol. 2019 Mar;80(3):176-183. doi: 10.1016/j.humimm.2018.12.011. Epub 2019 Jan 2.

PMID:
30610894
4.

Analysis of Risk Factors for Allograft Outcome Comparing 2 Kidneys From the Same Donor in Separate Recipients.

Radtke J, Scheidat S, Achilles EG, Li J, Fischer L, Herden U, Thaiss F, Wenzel U, Nashan B, Koch M.

Transplant Proc. 2018 Dec;50(10):3211-3215. doi: 10.1016/j.transproceed.2018.08.059. Epub 2018 Sep 5.

PMID:
30577187
5.

T-lymphocyte-specific knockout of IKK-2 or NEMO induces Th17 cells in an experimental nephrotoxic nephritis mouse model.

Guo L, Huang J, Chen M, Piotrowski E, Song N, Zahner G, Paust HJ, Alawi M, Geffers R, Thaiss F.

FASEB J. 2019 Feb;33(2):2359-2371. doi: 10.1096/fj.201800485RR. Epub 2018 Oct 4.

PMID:
30285578
6.

Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation.

Li J, Koch M, Kramer K, Kloth K, Abu Ganim AR, Scheidat S, Rinninger F, Thaiss F, Gulati A, Herden U, Achilles E, Fischer L, Nashan B.

Transpl Immunol. 2018 Oct;50:26-33. doi: 10.1016/j.trim.2018.06.001. Epub 2018 Jun 6.

PMID:
29885442
7.

Outcome and natural course of renal dysfunction in liver transplant recipients with severely impaired kidney function prior to transplantation.

Horvatits T, Pischke S, Proske VM, Fischer L, Scheidat S, Thaiss F, Fuhrmann V, Lohse AW, Nashan B, Sterneck M.

United European Gastroenterol J. 2018 Feb;6(1):104-111. doi: 10.1177/2050640617707089. Epub 2017 Apr 21.

8.

Prolonged IKKβ Inhibition Improves Ongoing CTL Antitumor Responses by Incapacitating Regulatory T Cells.

Heuser C, Gotot J, Piotrowski EC, Philipp MS, Courrèges CJF, Otte MS, Guo L, Schmid-Burgk JL, Hornung V, Heine A, Knolle PA, Garbi N, Serfling E, Evaristo C, Thaiss F, Kurts C.

Cell Rep. 2017 Oct 17;21(3):578-586. doi: 10.1016/j.celrep.2017.09.082.

9.

Systematic Comparison of IgM and IgG ABO Antibody Titers by Using Tube and Gel Card Techniques and its Relevance for ABO-Incompatible Kidney Transplantation.

Khalili I, Koch M, Thaiss F, Plaetke R, Bruegger J, Peine S.

Clin Lab. 2017 Sep 1;63(9):1393-1401. doi: 10.7754/Clin.Lab.2017.170229.

PMID:
28879711
10.
11.

Innate Immune Response in Kidney Ischemia/Reperfusion Injury: Potential Target for Therapy.

Kezić A, Stajic N, Thaiss F.

J Immunol Res. 2017;2017:6305439. doi: 10.1155/2017/6305439. Epub 2017 Jun 6. Review.

12.

Prostate cancer downregulated SIRP-α modulates apoptosis and proliferation through p38-MAPK/NF-κB/COX-2 signaling.

Yao C, Li G, Cai M, Qian Y, Wang L, Xiao L, Thaiss F, Shi B.

Oncol Lett. 2017 Jun;13(6):4995-5001. doi: 10.3892/ol.2017.6070. Epub 2017 Apr 21.

13.

Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective.

Cremaschi L, von Versen R, Benzing T, Wiesener M, Zink N, Milkovich G, Paivanas T, Gallagher M, Thaiss F.

Transpl Int. 2017 Oct;30(10):1011-1019. doi: 10.1111/tri.12991. Epub 2017 Jul 24.

14.

Incidence of BK polyomavirus infection after kidney transplantation is independent of type of immunosuppressive therapy.

Radtke J, Dietze N, Fischer L, Achilles EG, Li J, Scheidat S, Thaiss F, Nashan B, Koch M.

Transpl Infect Dis. 2016 Dec;18(6):850-855. doi: 10.1111/tid.12611. Epub 2016 Nov 30.

PMID:
27639176
15.

Lymphocyte-specific deletion of IKK2 or NEMO mediates an increase in intrarenal Th17 cells and accelerates renal damage in an ischemia-reperfusion injury mouse model.

Guo L, Lee HH, Noriega ML, Paust HJ, Zahner G, Thaiss F.

Am J Physiol Renal Physiol. 2016 Nov 1;311(5):F1005-F1014. doi: 10.1152/ajprenal.00242.2016. Epub 2016 Aug 31.

16.

Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation.

Pratschke J, Dragun D, Hauser IA, Horn S, Mueller TF, Schemmer P, Thaiss F.

Transplant Rev (Orlando). 2016 Apr;30(2):77-84. doi: 10.1016/j.trre.2016.02.002. Epub 2016 Feb 18. Review.

18.

The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients.

Massart A, Pallier A, Pascual J, Viklicky O, Budde K, Spasovski G, Klinger M, Sever MS, Sørensen SS, Hadaya K, Oberbauer R, Dudley C, De Fijter JW, Yussim A, Hazzan M, Wekerle T, Berglund D, De Biase C, Pérez-Sáez MJ, Mühlfeld A, Orlando G, Clemente K, Lai Q, Pisani F, Kandus A, Baas M, Bemelman F, Ponikvar JB, Mazouz H, Stratta P, Subra JF, Villemain F, Hoitsma A, Braun L, Cantarell MC, Colak H, Courtney A, Frasca GM, Howse M, Naesens M, Reischig T, Serón D, Seyahi N, Tugmen C, Alonso Hernandez A, Beňa L, Biancone L, Cuna V, Díaz-Corte C, Dufay A, Gaasbeek A, Garnier A, Gatault P, Gentil Govantes MA, Glowacki F, Gross O, Hurault de Ligny B, Huynh-Do U, Janbon B, Jiménez Del Cerro LA, Keller F, La Manna G, Lauzurica R, Le Monies De Sagazan H, Thaiss F, Legendre C, Martin S, Moal MC, Noël C, Pillebout E, Piredda GB, Puga AR, Sulowicz W, Tuglular S, Prokopova M, Chesneau M, Le Moine A, Guérif P, Soulillou JP, Abramowicz M, Giral M, Racapé J, Maggiore U, Brouard S, Abramowicz D.

Nephrol Dial Transplant. 2016 Jun;31(6):1002-13. doi: 10.1093/ndt/gfv437. Epub 2016 Jan 12.

PMID:
26763669
19.

Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.

Radtke J, Dietze N, Spetzler VN, Fischer L, Achilles EG, Li J, Scheidat S, Thaiss F, Nashan B, Koch M.

Transpl Infect Dis. 2016 Feb;18(1):79-88. doi: 10.1111/tid.12494. Epub 2016 Feb 3.

PMID:
26707694
20.

Inhibitor of NFκB Kinase Subunit 2 Blockade Hinders the Initiation but Aggravates the Progression of Crescentic GN.

Gotot J, Piotrowski E, Otte MS, Tittel AP, Linlin G, Yao C, Ziegelbauer K, Panzer U, Garbi N, Kurts C, Thaiss F.

J Am Soc Nephrol. 2016 Jul;27(7):1917-24. doi: 10.1681/ASN.2015060699. Epub 2015 Nov 16.

21.

CXCR3+ Regulatory T Cells Control TH1 Responses in Crescentic GN.

Paust HJ, Riedel JH, Krebs CF, Turner JE, Brix SR, Krohn S, Velden J, Wiech T, Kaffke A, Peters A, Bennstein SB, Kapffer S, Meyer-Schwesinger C, Wegscheid C, Tiegs G, Thaiss F, Mittrücker HW, Steinmetz OM, Stahl RA, Panzer U.

J Am Soc Nephrol. 2016 Jul;27(7):1933-42. doi: 10.1681/ASN.2015020203. Epub 2015 Nov 3.

22.

De novo mTOR inhibitor-based immunosuppression in ABO-incompatible kidney transplantation.

Koch M, Wiech T, Marget M, Peine S, Thude H, Achilles EG, Fischer L, Lehnhardt A, Thaiss F, Nashan B.

Clin Transplant. 2015 Nov;29(11):1021-8. doi: 10.1111/ctr.12624. Epub 2015 Oct 5.

PMID:
26333844
23.

High B-cell activating factor is not associated with worse 3-year graft outcome in blood group-incompatible kidney transplantation with rituximab induction.

Lehnhardt AM, Strecker M, Eiermann T, Marget M, Thaiss F, Nashan B, Koch M.

Clin Transplant. 2015 Apr;29(4):359-64. doi: 10.1111/ctr.12523. Epub 2015 Feb 18.

PMID:
25627801
24.

The effect of mTOR-inhibition on NF-κB activity in kidney ischemia-reperfusion injury in mice.

Kezic A, Becker JU, Thaiss F.

Transplant Proc. 2013 Jun;45(5):1708-14. doi: 10.1016/j.transproceed.2013.02.110.

PMID:
23769029
25.

Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations.

Alberti M, Valoti E, Piras R, Bresin E, Galbusera M, Tripodo C, Thaiss F, Remuzzi G, Noris M.

Am J Transplant. 2013 Aug;13(8):2201-6. doi: 10.1111/ajt.12297. Epub 2013 Jun 3.

26.

Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.

Koch M, Gräser C, Lehnhardt A, Pollok JM, Kröger N, Verboom M, Thaiss F, Eiermann T, Nashan B.

Transpl Int. 2013 Aug;26(8):e64-8. doi: 10.1111/tri.12120. Epub 2013 May 15.

27.

Effects of everolimus on oxidative stress in kidney model of ischemia/reperfusion injury.

Kezic A, Thaiss F, Becker JU, Tsui TY, Bajcetic M.

Am J Nephrol. 2013;37(4):291-301.

PMID:
23548777
28.

Intrinsic proinflammatory signaling in podocytes contributes to podocyte damage and prolonged proteinuria.

Brähler S, Ising C, Hagmann H, Rasmus M, Hoehne M, Kurschat C, Kisner T, Goebel H, Shankland S, Addicks K, Thaiss F, Schermer B, Pasparakis M, Benzing T, Brinkkoetter PT.

Am J Physiol Renal Physiol. 2012 Nov 15;303(10):F1473-85. doi: 10.1152/ajprenal.00031.2012. Epub 2012 Sep 12.

29.

Rho-kinase inhibition prevents proteinuria in immune-complex-mediated antipodocyte nephritis.

Meyer-Schwesinger C, Dehde S, Sachs M, Mathey S, Arefi K, Gatzemeier S, Balabanov S, Becker JU, Thaiss F, Meyer TN.

Am J Physiol Renal Physiol. 2012 Oct;303(7):F1015-25. doi: 10.1152/ajprenal.00380.2011. Epub 2012 Jul 18.

30.

[Long-term outcome with end-stage renal disease - survival is not enough: does dialysis or kidney transplantation matter?].

Schulz KH, Thaiss F.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Apr;55(4):543-51. doi: 10.1007/s00103-012-1450-2. German.

PMID:
22441524
31.

In vitro and in vivo proof of tolerance after two-step haploidentical bone marrow and kidney transplantation of the same donor.

Vondran FW, Eiermann T, Thaiss F, Schwinzer R, Nashan B, Koch M.

Transplantation. 2012 Mar 27;93(6):e23-5. doi: 10.1097/TP.0b013e3182492247. No abstract available.

PMID:
22406752
32.

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.

Kil LP, de Bruijn MJ, van Nimwegen M, Corneth OB, van Hamburg JP, Dingjan GM, Thaiss F, Rimmelzwaan GF, Elewaut D, Delsing D, van Loo PF, Hendriks RW.

Blood. 2012 Apr 19;119(16):3744-56. doi: 10.1182/blood-2011-12-397919. Epub 2012 Mar 1.

33.

Nephrotic syndrome and subepithelial deposits in a mouse model of immune-mediated anti-podocyte glomerulonephritis.

Meyer-Schwesinger C, Dehde S, Klug P, Becker JU, Mathey S, Arefi K, Balabanov S, Venz S, Endlich KH, Pekna M, Gessner JE, Thaiss F, Meyer TN.

J Immunol. 2011 Sep 15;187(6):3218-29. doi: 10.4049/jimmunol.1003451. Epub 2011 Aug 15.

34.

Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients.

Hutchinson JA, Riquelme P, Sawitzki B, Tomiuk S, Miqueu P, Zuhayra M, Oberg HH, Pascher A, Lützen U, Janssen U, Broichhausen C, Renders L, Thaiss F, Scheuermann E, Henze E, Volk HD, Chatenoud L, Lechler RI, Wood KJ, Kabelitz D, Schlitt HJ, Geissler EK, Fändrich F.

J Immunol. 2011 Sep 1;187(5):2072-8. doi: 10.4049/jimmunol.1100762. Epub 2011 Jul 29.

35.

Ubiquitin C-terminal hydrolase-l1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathy.

Meyer-Schwesinger C, Meyer TN, Sievert H, Hoxha E, Sachs M, Klupp EM, Münster S, Balabanov S, Carrier L, Helmchen U, Thaiss F, Stahl RA.

Am J Pathol. 2011 May;178(5):2044-57. doi: 10.1016/j.ajpath.2011.01.017.

36.

Bone marrow-derived progenitor cells do not contribute to podocyte turnover in the puromycin aminoglycoside and renal ablation models in rats.

Meyer-Schwesinger C, Lange C, Bröcker V, Agustian P, Lehmann U, Raabe A, Brinkmeyer M, Kobayashi E, Schiffer M, Büsche G, Kreipe HH, Thaiss F, Becker JU.

Am J Pathol. 2011 Feb;178(2):494-9. doi: 10.1016/j.ajpath.2010.10.024. Erratum in: Am J Pathol. 2011 Jul;179(1):537. Andina Agustian, Putri [corrected to Agustian, Putri Andina].

37.

Specific issues in living donor kidney transplantation: ABO - incompatibility.

Thaiss F.

Atheroscler Suppl. 2009 Dec 29;10(5):133-6. doi: 10.1016/S1567-5688(09)71828-8.

PMID:
20129392
38.

Prostaglandin EP2 and EP4 receptors modulate expression of the chemokine CCL2 (MCP-1) in response to LPS-induced renal glomerular inflammation.

Zahner G, Schaper M, Panzer U, Kluger M, Stahl RA, Thaiss F, Schneider A.

Biochem J. 2009 Aug 27;422(3):563-70. doi: 10.1042/BJ20090420.

PMID:
19570035
39.

ABO-incompatible kidney transplantation.

Thaiss F.

Wien Klin Wochenschr. 2009;121(7-8):227-9. doi: 10.1007/s00508-009-1165-z. No abstract available.

PMID:
19562277
40.

Resolution of renal inflammation: a new role for NF-kappaB1 (p50) in inflammatory kidney diseases.

Panzer U, Steinmetz OM, Turner JE, Meyer-Schwesinger C, von Ruffer C, Meyer TN, Zahner G, Gómez-Guerrero C, Schmid RM, Helmchen U, Moeckel GW, Wolf G, Stahl RA, Thaiss F.

Am J Physiol Renal Physiol. 2009 Aug;297(2):F429-39. doi: 10.1152/ajprenal.90435.2008. Epub 2009 May 20.

41.

Rho kinase inhibition attenuates LPS-induced renal failure in mice in part by attenuation of NF-kappaB p65 signaling.

Meyer-Schwesinger C, Dehde S, von Ruffer C, Gatzemeier S, Klug P, Wenzel UO, Stahl RA, Thaiss F, Meyer TN.

Am J Physiol Renal Physiol. 2009 May;296(5):F1088-99. doi: 10.1152/ajprenal.90746.2008. Epub 2009 Feb 18.

42.

Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice.

Benndorf RA, Krebs C, Hirsch-Hoffmann B, Schwedhelm E, Cieslar G, Schmidt-Haupt R, Steinmetz OM, Meyer-Schwesinger C, Thaiss F, Haddad M, Fehr S, Heilmann A, Helmchen U, Hein L, Ehmke H, Stahl RA, Böger RH, Wenzel UO.

Kidney Int. 2009 May;75(10):1039-49. doi: 10.1038/ki.2009.2. Epub 2009 Feb 11.

43.

Immediate versus long-term effect of rituximab in recurrent focal segmental glomerulosclerosis.

Meyer TN, Thaiss F, Stahl RA.

Transpl Int. 2008 Nov;21(11):1102. doi: 10.1111/j.1432-2277.2008.00718.x. Epub 2008 Jun 18. No abstract available.

44.

Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.

Steinmetz OM, Lange-Hüsken F, Turner JE, Vernauer A, Helmchen U, Stahl RA, Thaiss F, Panzer U.

Transplantation. 2007 Oct 15;84(7):842-50.

PMID:
17984836
45.
46.

A new mouse model of immune-mediated podocyte injury.

Meyer TN, Schwesinger C, Wahlefeld J, Dehde S, Kerjaschki D, Becker JU, Stahl RA, Thaiss F.

Kidney Int. 2007 Oct;72(7):841-52. Epub 2007 Jul 25.

47.
48.

Angiotensin II upregulates toll-like receptor 4 on mesangial cells.

Wolf G, Bohlender J, Bondeva T, Roger T, Thaiss F, Wenzel UO.

J Am Soc Nephrol. 2006 Jun;17(6):1585-93. Epub 2006 May 4.

49.

Compartment-specific expression and function of the chemokine IP-10/CXCL10 in a model of renal endothelial microvascular injury.

Panzer U, Steinmetz OM, Reinking RR, Meyer TN, Fehr S, Schneider A, Zahner G, Wolf G, Helmchen U, Schaerli P, Stahl RA, Thaiss F.

J Am Soc Nephrol. 2006 Feb;17(2):454-64. Epub 2005 Dec 28.

50.

Renal failure and hypertension in Alagille syndrome with a novel JAG1 mutation.

Harendza S, Hübner CA, Gläser C, Burdelski M, Thaiss F, Hansmann I, Gal A, Stahl RA.

J Nephrol. 2005 May-Jun;18(3):312-7.

PMID:
16013021

Supplemental Content

Loading ...
Support Center